An Ignoble Experiment: Alzheimer's drug shows promise in early results of study

2022/09/29

Alzheimer's drug shows promise in early results of study

HEALTH & COVID-19 NEWS

Sep 29, 2022

FILE — The Biogen Inc., headquarters is shown March 11, 2020, in Cambridge, Mass. Shares of Biogen and other drugmakers researching Alzheimer's disease soared early Wednesday, Sept. 28, 2022, after Japan's Eisai Co. said its potential treatment appeared to slow the fatal disease's progress in a late-stage study. Eisai announced results late Tuesday from a global study of nearly 1,800 people with early-stage Alzheimer's (AP Photo/Steven Senne, File)

Alzheimer's drug shows promise in early results of study

Shares of Biogen and other drugmakers researching Alzheimer's disease soared early Wednesday after Japan's Eisai Co. said its potential treatment appeared to slow the fatal disease's progress in a late-stage study More »

MORE STORIES

Close-up photo of gloved hands holding a Pfizer COVID-19 vaccine booster shot, administered as the Mount Sinai South Nassau Vaxmobile vists Freeport High School, in Freeport, New York on Nov. 30, 2021.

Rising COVID-19 cases in the UK may be a warning for the US »

Closed gates are seen at the U.S./Canada border in Lansdowne, Ontario, on March 22, 2020.

Canada won't require masks on planes, drops vaccine mandate »

Pfizer seeks to expand omicron booster to 5- to 11-year-olds »

Study: New Alzheimer's diagnoses more common in seniors who have had COVID-19 »

MANAGE YOUR ACCOUNT

If you'd like to receive some of our other email newsletters, you can tap or click the links below:

Be among the first to receive National Breaking News or Local Breaking News as stories break.
Catch up on the day's big stories with our Morning Headlines and Afternoon Digest newsletters.
Receive our Daily Forecasts or get Severe Weather Alerts sent straight to your email inbox.